A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.

Abstract

BACKGROUND\nA high number of combinations of PD-1/PD-L1 inhibitors with other anti-cancer therapies are in clinical development. The usefulness of phase II trials in evaluating their efficacy and safety is unclear.\n\n\nMATERIALS AND METHODS\nWe performed a systematic search on PubMed and Cochrane Library for phase II trials of PD-1/PD-L1 inhibitors in combination with other anti-cancer therapies (systemic therapy and/or radiotherapy) published between January 1st 2018 and December 31st 2020. Study design, primary endpoint and main outcomes were registered for each paper.\n\n\nRESULTS\n119 articles reporting on 65 regimens were included in our analysis. Backbone agents were more frequently PD-1 inhibitors (pembrolizumab\xa0=\xa047, nivolumab\xa0=\xa041, camrelizumab\xa0=\xa03) followed by anti-PD-L1 (durvalumab\xa0=\xa019, atezolizumab\xa0=\xa06, avelumab\xa0=\xa03). Therapeutic partners were other immunotherapeutic agents (n\xa0=\xa046), targeted therapies (n\xa0=\xa040), chemotherapy (n\xa0=\xa022) or radiotherapy (n\xa0=\xa011). The majority of articles reported on single-arm trials (n\xa0=\xa087, 73%) and response rate was the most frequent primary endpoint (n\xa0=\xa069, 58%). Objective responses, registered in 109 (92%) articles, ranged between 0% and 91%. The incidence of grade 3 or higher treatment-related adverse events, clearly reported in 97 (82%) articles, spanned from 0 to 100%. Five combinations received regulatory approval by Food and Drug Administration or European Medicine Agency for 9 different indications, based on the results of a phase II trial (n\xa0=\xa03) or on a confirmatory phase III trial (n\xa0=\xa06).\n\n\nCONCLUSIONS\nThe landscape of phase II trials evaluating PD-1/PD-L1 inhibitors with other anticancer therapies is heterogeneous. Combinations of two immunotherapeutic agents have been the most investigated. Only a minority of indications (8%) granted regulatory approval.